{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:57:13Z","timestamp":1791881833513,"version":"4.3.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    Real-world amyloid-related imaging abnormality (ARIA) rates with lecanemab are consistently lower than in the Clarity AD trial, yet whether this reduction is genotype-specific is unknown. We compared published\n                    <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                    \u03b54-stratified ARIA-E and ARIA-H rates from Clarity AD with a US real-world cohort and Japanese post-marketing surveillance. ARIA rates were largely unchanged in\n                    <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                    \u03b54 noncarriers, whereas reductions were concentrated among carriers, especially homozygotes. This pattern was observed for both ARIA subtypes across both settings. These early real-world findings suggest that the apparent attenuation of ARIA during the initial clinical introduction of lecanemab is consistent with genotype-informed risk selection rather than a uniform population-wide decrease.\n                  <\/jats:p>","DOI":"10.1177\/13872877261480386","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:22:06Z","timestamp":1788276126000},"page":"1614-1618","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["<i>APOE<\/i>\n                    \u03b54 genotype\u2013dependent reduction of amyloid-related imaging abnormality in real-world lecanemab use: Implications for risk-stratified prescribing"],"prefix":"10.1177","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-5401","authenticated-orcid":false,"given":"YongSoo","family":"Shim","sequence":"first","affiliation":[{"name":"Department of Neurology, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Kyung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurology, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_3_3_4_2","volume-title":"Alzheimer\u2019s Association International Conference (AAIC)","author":"Schindler S","year":"2025","unstructured":"Schindler S, Tousi B, Weisman D, et al. Two-year real-world study of LEQEMBI in the United States. In: Alzheimer\u2019s Association International Conference (AAIC). 2025. https:\/\/www.eisai.com\/news\/2025\/news202552.html."},{"key":"e_1_3_3_5_2","article-title":"AAIC Presentations Provide Context on Lecanemab\u2019s Real-World Effect 2 Years Since Approval","author":"Meglio M","year":"2025","unstructured":"Meglio M. AAIC Presentations Provide Context on Lecanemab\u2019s Real-World Effect 2 Years Since Approval. Neurology Live 2025. https:\/\/www.neurologylive.com\/view\/aaic-poster-provides-context-lecanemab-real-world-effect-2-years.","journal-title":"Neurology Live"},{"key":"e_1_3_3_6_2","unstructured":"Iwata A Sakata Y Koizumi K et al. Interim analysis of post-marketing observational study of lecanemab in Japan. Clinical Trials on Alzheimer\u2019s Disease (CTAD). San Diego 2025. https:\/\/www.mayvillemedical.com\/iwata-2025-ctad-presentation."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100541"},{"key":"e_1_3_3_8_2","volume-title":"43rd Annual Meeting of the Japanese Society for Dementia Research (JSDR) Koriyama, Fukushima","author":"Nakagawa M","year":"2024","unstructured":"Nakagawa M, Torii K, Ogawa T. Clarity AD: safety of lecanemab in Japanese subjects with early Alzheimer\u2019s disease. In: 43rd Annual Meeting of the Japanese Society for Dementia Research (JSDR) Koriyama, Fukushima. 2024. https:\/\/square.umin.ac.jp\/jsdr43\/."}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261480386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877261480386","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261480386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:43:12Z","timestamp":1791880992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877261480386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/13872877261480386"],"URL":"https:\/\/doi.org\/10.1177\/13872877261480386","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}